Horizon Europe Health 2027 – cell-free biological synthesis
This Horizon Europe Health topic funds collaborative development of cell-free protein synthesis platforms for the discovery or production of biologic medicines. It addresses barriers to using these platforms at a…
This Horizon Europe Health topic funds collaborative development of cell-free protein synthesis platforms for the discovery or production of biologic medicines. It addresses barriers to using these platforms at a scale and quality suitable for medicine development and manufacturing. Projects should connect the platform development work to a defined therapeutic application and a credible path to use.
Who can apply
The topic is relevant to consortia bringing together biotechnology companies, research organisations and manufacturing or translational partners. UK organisations can participate as Horizon Europe associated-country partners, subject to the topic’s consortium and eligibility rules.
How to apply
Submit a full proposal through the EU Funding and Tenders Portal under topic HORIZON-HLTH-2027-01-IND-01. The single-stage deadline is 5pm Brussels time on 17 February 2027. The work programme indicates an EU contribution of €6 million to €8 million per project. The topic documents set out the expected outcomes and consortium requirements.
- Funding Organisation
- European Commission / HaDEA
- Status
- Open
- Open date
- 29 October 2026
- Closing date
- 17 February 2027
- Funder type
- Government
- Funding type
- Grant
- Eligible organisation
- Companies, Higher Education Institution (HEI), Other
- Geographic eligibility
- Europe, UK
- Area in health
- Other, Therapeutics
- Use of funding
- Product Development, Research